COO:NASDAQThe Cooper Companies, Inc. Analysis
Data as of 2026-06-10 - not real-time
$68.62
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The stock is trading below its longer‑term moving average while still above the short‑term average, a classic bearish crossover. Momentum indicators show the RSI perched in the upper range, suggesting overbought conditions. The MACD histogram is positive and the signal line has turned bullish, offering a modest technical upside. Price sits near a historically observed support zone, with the next resistance level a few dollars higher. Volatility has been elevated over the past month, while beta remains modest, indicating price swings but limited market‑wide correlation. Fundamental metrics reveal a price‑to‑earnings multiple far above the sector average, and a discounted cash‑flow model points to a valuation substantially lower than the current market price.
Recent earnings disclosed a record revenue increase and an earnings‑per‑share surprise, reinforcing the analyst consensus buy rating. However, operating margins remain negative and the company carries a sizable debt load relative to its equity, which tempers profitability outlook. Cash balances are modest compared with total debt, limiting financial flexibility. The business benefits from diversified segments—contact lenses and women’s health devices—providing resilience but also exposing it to regulatory scrutiny. Geographic exposure includes softness in the Asia‑Pacific market, adding a layer of regional risk. With no dividend and a growth‑oriented profile, the stock appeals mainly to investors seeking capital appreciation rather than income.
Recent earnings disclosed a record revenue increase and an earnings‑per‑share surprise, reinforcing the analyst consensus buy rating. However, operating margins remain negative and the company carries a sizable debt load relative to its equity, which tempers profitability outlook. Cash balances are modest compared with total debt, limiting financial flexibility. The business benefits from diversified segments—contact lenses and women’s health devices—providing resilience but also exposing it to regulatory scrutiny. Geographic exposure includes softness in the Asia‑Pacific market, adding a layer of regional risk. With no dividend and a growth‑oriented profile, the stock appeals mainly to investors seeking capital appreciation rather than income.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- technical bearish crossover
- elevated volatility
- price near support level
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- earnings beat and revenue growth
- strong cash flow generation
- analyst consensus buy
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- diversified product portfolio
- long‑term industry tailwinds
- manageable beta and liquidity
Key Metrics & Analysis
Financial Health
Revenue Growth7.90%
Profit Margin5.57%
P/E Ratio58.2
ROE2.85%
ROA2.52%
Debt/Equity33.09
P/B Ratio1.6
Op. Cash Flow$953.0M
Free Cash Flow$424.3M
Industry P/E24.9
Technical Analysis
TrendBearish
RSI68.0
Support$58.89
Resistance$69.00
MA 20$61.94
MA 50$64.79
MA 200$72.79
MACDBullish
VolumeIncreasing
Fear & Greed Index83.89
Valuation
Fair Value$26.39
Target Price$80.57
Upside/Downside17.42%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.64
Volatility34.45%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.